Dipeptides injected intravenously or added to liver perfusion medium were hydrolyzed rapidly to amino acids. The clearance volumes per min of plasma Gly-Phe and Gly-Lys were 63 % and 224%, respectively, of the total plasma volume. These values far exceed the blood flow in any single organ, suggesting that several organs must be involved in peptide assimilation. Intravenous administration of peptides increased the levels of their constituent amino acids in organs. Two possible explanations for this were assimilation of the peptides by the organs, and transport into the organs of the amino acids generated by extracellular hydrolysis of the peptides. The former possibility was tested by eliminating plasma lysine by enzymic degradation, so that the amino acid would accumulate only in the organs that assimilate lysine-containing peptides. Results showed that all organs tested, except the brain, had an intrinsic ability to assimilate peptides.
Materials. Dipeptides were purchased from Sigma Chemical (St. Louis, U.S.A.). Two peptide samples, SWH-1 and SWH-2, with average sizes of 20 and 4.5, respectively, were supplied by Fuji Oil and Food Inc. (Osaka, Japan). Both samples were protease treated products that had been extracted from defatted soybeans at an acidic pH. All other reagents were of analytical grade and were obtained from local sources. For measurement of dipeptide content, 0.1 volume of 5.5 N perchloric acid was added to the perfusate or plasma, and the mixture was neutralized with potassium hydroxide. The resultant precipitate was removed by centrifugation, and the supernatant was used for the assay of dipeptides.
Analytical methods. Dipeptides were determined by high performance liquid chromatography (HPLC). Blood extracts and perfusate samples were loaded on a reverse phase column (Shimpack CLC-ODS, Shimadzu Inc., Kyoto, Japan) equilibrated with 8% acetonitrile containing 0.1% trifluoroacetic acid, and the absorbance of the eluate at 210 nm was monitored with a Shimadzu SPD-6A spectrophotometric detector. Lysine was assayed in a coupled assay using lysine -a-oxidase and peroxidase, or in a Hitachi KLA-5 amino acid analyzer. Fig. 2 . Degradation of dipeptides in the systemic circulation of rats. Gly-Phe(a) or Gly-Lys(b) at 0.5mmol/kg was injected into the femoral vein of rats, and blood samples were collected at the indicated intervals through a cannula inserted into the femoral artery for determination of the plasma levels of the peptides. Organ assimilation of peptides The cytoplasm of cells contains high hydrolase activity, so peptides per se would not be expected to accumulate intracellularly, even if they entered cells directly. Thus an organ can be assumed to assimilate a peptide if application of peptide brings about an increase in the intracellular levels of its constituent amino acids. However, intravenous injection of a peptide resulted in rapid hydrolysis of the peptide, with a simultaneous increase in the levels of its constituent amino acids in the plasma (data not shown). These free amino acids in the bloodstream make it difficult to identify organs that have the ability to assimilate peptides, as all organs of the body, including those that cannot themselves assimilate peptides, can take up free amino acids. To overcome this problem, i.e., to identify organs that can take up peptides in the absence of their free, constituent amino acids, we used an enzyme that degraded an amino acid but did not act on this amino acid in peptides.
RESULTS

Degradation
The enzymic degradation of amino acids exhibits Michaelis-Menten type kinetics: The equation indicates that, under these conditions, the degradation rate is directly proportional to the concentration of the amino acid with the first-order rate constant k= Vmax/Km. From this, the half-life of an amino acid is obtained as T=log2/k, suggesting that an amino acid can be essentially eliminated from the blood if k is sufficiently large. As an example of an enzyme with such a k value, we chose lysine-a-oxidase (Lys-Oxidase), which catalyzes the oxidative deamination of lysine with a k value of about 1650 (Km=0.04 mM, Vmax=66IU/mg) (7). We injected 100 IU of Lys-Oxidase intraperiotoneally into mice, and measured the time course of its change in activity in the blood. As shown in Fig. 3 , the activity of Lys-Oxidase reached a maximum of about 1 IU per ml of plasma about two hours after its injection. At this time, the half-life of lysine should be 2.5 sec (Vmax=1IU/ml=1mM/min, Km=0.04mM, k=25min 1, thus T=log2/25min), indicating that free lysine should be completely eliminated from the plasma. Therefore we administered peptides containing 0.5mmol/kg of lysine at this time, and 15 min later excised organs to measure their lysine content. Under these conditions, lysine should accumulate only in the organs that can assimilate the peptide. We used the lysine containing peptides Gly-Lys, SWH-1 (average peptide size, 20), and SWH-2 (average peptide size, 4.5), and investigated the accumulation of lysine in (a)the liver, (b)kidney, (c)jejunum, (d)skeletal muscle, and (e)brain (Fig. 4) . In the liver, application of lysine alone increased the lysine content (a-2), but treatment with Lys-Oxidase prevented its accumulation (a-4). However, on treatment with Lys-Oxidase and Gly-Lys instead of free the liver content of lysine increased (a-5). The smaller peptide (SWH-2) was also assimilated by the liver, although to a lesser extent (a-6), but a much larger peptide (SWH 1) was not assimulated (a-7). Similar patterns of peptide assimilation were observed in all other organs except the brain, in which the lysine content was increased in the presence of S84 K. KUROSAWA et al. Fig. 3 . Time course of change in plasma activity of Lys -a-oxidase, Lys -a-oxidase was injected at 100IU/kg into the intraperitoneal cavity of mice, and the time course of change in its plasma activity was measured. Fig. 4 . Organ assimilation of peptides. Two hours after intraperitoneal injection of Lys -aoxidase (see legend for Fig. 3 ), lysine or a peptide was injected intraperitoneally into mice, at 0.5mmol lysine/kg. After 15min, (a)the liver, (b)kidney, (c)jejunum, (d)skeletal muscle, and (e)brain were excised, and their lysine content was measured.
(1)saline only as a control, (2)lysine only, (3)Lys -a-oxidase only, (4)Lys -a-oxidase and lysine, (5)Lys -a-oxidase and Gly-Lys, (6)Lys -a-oxidase and SWH-2, (7)Lys -a-oxidase and SWH-1. 
DISCUSSION
In the present study, we observed that dipeptides were rapidly hydrolyzed to amino acids in perfused liver and in the systemic circulation, and from analyses of the rate of plasma peptide clearance we concluded that several organs must be involved in their degradation. This conclusion was confirmed by direct demonstration that intravenous injection of lysine-containing peptides resulted in accumulation of lysine in all organs except the brain, even when free lysine was eliminated from the plasma. Lysine was eliminated from the plasma by enzymic degradation, and its complete elimination was validated by determination of its half-life based on enzymic kinetics.
The mechanisms involved in the cellular uptake of peptides are still uncertain. Peptides may be transported into cells via a peptide carrier and then hydrolyzed by cytoplasmic peptidases, or they may be decomposed to amino acids by plasma membrane peptidases, and the resultant amino acids may then be transported into the cytosol through amino acid channels. In studies on liver, Alibi's group reported that hydrolase activity released from the cell membrane or cytosol could account for peptide degradation in the perfusion medium or in the plasma, and that, in contrast to the behavior of amino acids, no entry of dipeptide into plasma membrane vesicles was observed (2) . From these results they concluded that there was no dipeptide carrier on the plasma membrane of the liver, and that the liver assimilates dipeptides after their extracellular hydrolysis to amino acids (2, 4) . However, leakage of enzymes means disruption of cell membranes, and this is inevitably accompanied by the release of other cytosolic components, as well as peptidase(4). In our experiments, scarcely any activity of peptidases or of other cytosolic enzymes, such as alanine aminotransferase and lactate dehydrogenase, was detected in the liver perfusion medium. Thus, it is more likely that plasma peptides are degraded by peptidases on the cell membranes or in the cytosol when they come into contact with the endothelial cells of capillaries or the parenchymal cells of organs during their circulation. Moreover, our demonstration that organs can assimilate peptides in the absence of free amino acids suggests the direct entry of peptides into cells.
It is also noteworthy that the rates of degradation of peptides in the liver perfusion medium were found to differ greatly, depending on their constituent amino acids. Lombardo et al. reported that dipeptides containing glycine were relatively resistant to hydrolysis, and that replacement of glycine by alanine at either the N or C terminus of dipeptides significantly reduced their half-lives in the perfusion medium and in plasma (2) . We confirmed their results, and observed further that leucyl-dipeptides tended to be degraded more rapidly than alanyl-dipeptides. At present we have no explanation for this phenomenon; probably the specificity of the peptidase in the cell membrane, and/or the hydrophobic interaction of peptides with the membrane, is related to the efficiency of the enzyme action.
As shown by Alibi's group, dipeptides are nutritionally equivalent to their Vol. 37, Supplement, 1991 corresponding amino acids (3). However, the assimilation of much larger peptides has not been investigated extensively. In this study, we demonstrated that many organs can assimilate not only dipeptides, but also SWH-2, a mixture of peptides with an average size of 4.5. In addition, we observed that, after intravenous injection of SWH-2, the disappearance rates of its constituent peptides were similar to those of dipeptides (our unpublished data). This indicates that the body as a whole can assimilate almost all types of small peptides. Thus, from the nutritional view point, plasma peptides of appropriate size would seem to be equivalent to their constituent amino acids.
